1. Home
  2. HIO vs PRTC Comparison

HIO vs PRTC Comparison

Compare HIO & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset High Income Opportunity Fund Inc.

HIO

Western Asset High Income Opportunity Fund Inc.

HOLD

Current Price

$3.75

Market Cap

368.0M

Sector

Finance

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIO
PRTC
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.0M
386.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HIO
PRTC
Price
$3.75
$16.91
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
305.3K
4.8K
Earning Date
01-01-0001
08-28-2025
Dividend Yield
10.33%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
N/A
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$7.87
Revenue Growth
N/A
1265.60
52 Week Low
$3.52
$13.30
52 Week High
$4.03
$23.35

Technical Indicators

Market Signals
Indicator
HIO
PRTC
Relative Strength Index (RSI) 42.70 51.09
Support Level $3.75 $16.44
Resistance Level $3.88 $17.17
Average True Range (ATR) 0.03 0.35
MACD 0.00 0.12
Stochastic Oscillator 38.89 55.29

Price Performance

Historical Comparison
HIO
PRTC

About HIO Western Asset High Income Opportunity Fund Inc.

Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: